Introduction Diagnosis of antiphospholipid syndrome (APS) still remains a laboratory
challenge due to the great diversity of antiphospholipid antibodies (aPL) and their …

Objective To assess the value of a combination of anti–β2‐glycoprotein I (anti‐β2 GPI)
domain I antibody and anti–phosphatidylserine/prothrombin complex (anti‐PS/PT) antibody …

Background Despite expansion in the 2006 Sydney antiphospholipid syndrome (APS)
classification criteria to include IgG/IgM anti-β2-glycoprotein (aβ2GPI) antibodies in addition …

Background Antiphospholipid antibodies (aPL) can be detected in asymptomatic carriers
and infectious patients. The aim was to investigate whether a novel line immunoassay (LIA) …

We read with great interest the article by Otomo et al, which provided a formula for improved
risk assessment in patients with APS by determining the aPL-S (1). Their addition of assays …

Objective It has been suggested that only antibodies against domain 1 (D1) of β2‐
glycoprotein I (β2GPI) are pathogenic and diagnostic. The role of antibodies against other …

OBJECTIVE: To describe baseline characteristics of antiphospholipid antibody (aPL)-
positive patients, overall and by clinical and laboratory subtypes, enrolled in an international …

The clinical spectrum of the anti-phospholipid syndrome (APS) is not limited to vascular
thrombosis or miscarriages but includes additional manifestations that cannot be explained …

Objective To describe the baseline characteristics of patients with positivity for
antiphospholipid antibodies (aPLs) who were enrolled in an international registry, the …

The antiphospholipid syndrome (APS) is an autoimmune disease defined by the co-
occurrence of clinical and serological symptoms [presence of at least one of the …